Big Pharma's Second Life
Drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at a CBI event in The Triangle.
Can big pharma solve its fixed cost problem by going virtual? Not entirely, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at CBI's Sponsor/CRO Systems & Business Process Integration conference in The Triangle.
Check out the full article on our sister site, Pharmaceutical Executive.
Related Content
